Affinity Asset Advisors’s Tourmaline Bio TRML Stock Holding History

Affinity Asset Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100,000	Closed	-$1.52M	–	114
2025 Q1	$1.52M	Buy	+100,000	New	+$1.6M	0.15%	72

Other funds holding TRML

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Affinity Asset Advisors's TRML Position: Q2 2024 in Review

Affinity Asset Advisors sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 50,000 shares — an estimated $1.15M sold.

Affinity Asset Advisors first reported a position in TRML in Q2 2023 and held it in 4 quarters. The position peaked at $1.78M in Q4 2023. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

Affinity Asset Advisors reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
Affinity Asset Advisors sold 50,000 Tourmaline Bio shares in Q2 2024, an estimated $1.15M.
Affinity Asset Advisors first reported a position in Tourmaline Bio in Q2 2023 and held it in 4 quarters.
Affinity Asset Advisors's Tourmaline Bio position peaked at $1.78M in Q4 2023.
84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Affinity Asset Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.